Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the cost-effectiveness of low dose statins for primary prevention of vascular disease, incorporating current prices, non-adherence (reduced clinical efficacy while maintaining healthcare costs), and the results of the recently published JUPITER trial. DESIGN: Cost-effectiveness analysis using a Markov model. Sensitivity analyses and Monte Carlo simulation evaluated the robustness of the results. SETTING: Primary care in The Netherlands. PARTICIPANTS: Hypothetical populations of men and women aged 45 to 75 years without a history of vascular disease at different levels of risk for vascular disease (myocardial infarction and stroke) over 10 years. INTERVENTIONS: Low dose statin treatment daily versus no treatment for 10 years. MAIN OUTCOME MEASURES: Number of fatal and nonfatal vascular events prevented, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios over 10 years. RESULTS: Over a 10-year period, statin treatment cost €35 000 (£30 000, $49 000) per QALY gained for men aged 55 years with a 10-year vascular risk of 10%. The incremental cost-effectiveness ratio improved as risk for vascular disease increased. The cost per QALY ranged from approximately €5000 to €125 000 when the 10-year vascular risk for men aged 55 years was varied from 25% to 5%. The incremental cost-effectiveness ratio slightly decreased with age after the level of vascular risk was specified. Results were sensitive to the costs of statin treatment, statin effectiveness, non-adherence, disutility of taking medication daily, and the time horizon of the model. CONCLUSIONS: In daily practice, statin treatment seemed not to be cost-effective for primary prevention in populations at low risk of vascular disease, despite low costs of generic drug pills. Adherence to statin treatment needs to be improved to enhance the cost-effectiveness of the use of statins for primary prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“by examining the effect of non-adherence, examining a greater number of subgroups, and including generic statin prices and updated estimates of statin effectiveness. This analysis incorporates the results from the recently published JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Tri…”
ResultEffect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Statin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808 · cited 1×
“The risks of adverse effects associated with statins (myopathy and rhabdomyolysis) were drawn from a systematic review of cohort studies supported by data from randomised controlled trials.”
MethodBrugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · cited 1×
“Four recent systematic reviews focused on the efficacy of statins in primary prevention populations at high risk, and concluded that statin treatment was associated with a significant reduction in the risk of major vascular events, but it had no benefit on all cause mortality.”
BackgroundA systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446 · cited 1×
“Four recent systematic reviews focused on the efficacy of statins in primary prevention populations at high risk, and concluded that statin treatment was associated with a significant reduction in the risk of major vascular events, but it had no benefit on all cause mortality.”
BackgroundPrimary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00007 · Cited by 204
Long-term persistence with statin therapy: A nationwide register study in Finland
Helin-Salmivaara, A., Lavikainen, P., Korhonen, M. J., Halava, H., Junnila, S. Y. T., Kettunen, R., Neuvonen, P. J., Martikainen, J. E., Ruokoniemi, P., & Saastamoinen, L. K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.12.003 · Cited by 76
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
McCowan, C., Wang, S., Thompson, A. M., Makubate, B., & Petrie, D. J. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.464 · Cited by 137
“In another field, improving adherence to statins would enhance cost-effectiveness, with a projected decrease in incremental cost per QALY gained from h35 000 to h26 000 for complete adherence (Greving et al, 2011).”
BackgroundResultStevanović, J., O’Prinsen, A. C., Verheggen, B. G., Schuiling-Veninga, N., Postma, M. J., & Pechlivanoglou, P. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.01.008 · Cited by 12
Metadata
- Authors
- Greving, J., Visseren, F., de Wit, G., & Algra, A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2011-03-30
- Volume
- 342
- Issue
- mar30 3
- Pages
- d1672-d1672
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2044064409
- Cited by
- 113
- References
- 10
- FWCI
- 15.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.